Open-label, phase I dose-escalation study of sodium selenate, a novel activator of PP2A, in patients with castration-resistant prostate cancer
NM Corcoran, CM Hovens, M Michael, MA Rosenthal, AJ Costello
British Journal of Cancer | NATURE PUBLISHING GROUP | Published : 2010
We acknowledge the assistance of the following people in the initial design and conduct of the studies: Grant Morley, Patricia Bugeja and Helen Crowe. This work was financially supported by Velacor Therapeutics Pty Ltd in their role as sponsor.